Meta-analysis of the cardiovascular benefits of intensive lipid lowering with statins

Acta Neurologica Scandinavica

Volumn 124, Issue 3, 2011, Pages 188-195

  Chan, D K Y ^a,b   O'Rourke, F ^a   Shen, Q ^a,b   Mak, J C S ^a   Hung, W T ^c  

^a BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

Cardiovascular events; Intensive lipid lowering therapy; Low density lipoprotein; Stroke

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; DRUG EFFICACY; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; STROKE;

CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; INCIDENCE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 79961211178     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2010.01450.x     Document Type: Article

References (35)

1. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature deaths from coronary heart disease continuous and graded? Findings in 356, 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256:2823-8.
2. Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. Br Med J 1991;303:276-82.
3. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-74.
4. De Lemos JA, Blazing MA, Wiviott SD et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndrome Phase Z of the A to Z trial. JAMA 2004;292:1307-16.
5. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Eng J Med 2004;350:1495-504.
6. Pedersen TR, Faergeman O, Kastelein JJ et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction The IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-45.
7. The stroke prevention by aggressive reduction in cholesterol level (SPARCL) investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Eng J Med 2006;355:549-59.
8. LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Eng J Med 2005;352:1425-35.
9. Deedwania P, Stone PH, Noel Bairey Merz C et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease Results of the study assessing goals in the elderly (SAGE). Circulation 2007;115:700-7.
10. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Eng J Med 2008;359:2195-207.
11. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
12. Grundy SM, Cleeman JI, Merz CNB et al. National Heart, Lung and Blood Institute, American College of Cardiology Foundation, American Heart Association. Implications of recent trials for National Cholesterol Education program Adult Treatment Panel III Guidelines. Circulation 2004;110:227-39.
13. National Heart Foundation of Australia. Cardiac Society of Australia and New Zealand National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management - 2005. Heart, Lung & Circulation 2005;14:275-91.
14. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analysis of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 1999;354:1896-900.
15. Gustafson TL True Epistat Reference Manual, Texas, USA: Epistat Services, Chapter 14, 1994.
16. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
17. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
18. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
19. The PostCoronaryArteryBypassGraftTrialInvestigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336:153-62.
20. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.
21. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
22. GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico). Results of the low-dose (20mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge?. Ital Heart J 2000;1:810-20.
23. Serruys PW, De Feyter P, Macaya C et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;287:3215-22.
24. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
25. Shepherd J, Blauw GJ, Murphy MB et al. PROspective Study of Pravastatin in the Elderly at Risk Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.
26. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA 2002;288:2998-3007.
27. Sever PS, Dahlöf B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
28. Holdaas H, Fellström B, Jardine AG et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003;361:2024-31.
29. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
30. Olsson AG, Schwartz GG, Szarek M, Luo D, Jamieson MJ Effects of high-dose atorvastatin in patients ≥65years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study). Am J Card 2007;99:632-5.
31. Wenger NK, Lewis SJ, Herrington DM, Bittner V, Welty FK, for the Treating to New Targets Study Steering Committee and Investigators. Outcomes of using high- or low-dose Atorvastatin in patients 65years of age or older with stable coronary heart disease. Ann Intern Med 2007;147:1-9.
32. Ko DT, Mamdani M, Alter DA Lipid-lowering therapy with statins in high-risk elderly patients The treatment-risk paradox. JAMA 2004;291:1864-70.
33. Orken DN, Kenangil G, Celik M et al. Association of low cholesterol with primary intracerebral haemorrhage: a case control study. Acta Neurol Scand 2009; 119:151-4.
34. Yano K, Reed DM, MaClean CJ Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. Stroke 1989;20:1460-5.
35. Hegland O, Kurz MW, Munk PS, Larsen JP The effect of statin therapy on the progression of carotid artery stenosis in relation to stenosis severity. Acta Neurol Scand 2010;121:11-5.